The efficacy of quadruple and GLP-1RA therapy

148 Patients who switched to quadruple or GLP-1RA therapy during study period

96 Study population

52 Excluded patients
- 24 Missing data on HbA1c
- 2 Follow-up loss
- 7 Low C-peptide (<0.6 ng/mL)
- 5 Those who did not maintain quadruple therapy (high out-of-pocket payment)
- 8 Those who did not maintain GLP-1RA therapy (refusal of injectable therapy)
- 2 Secondary hyperglycemia (steroid)
- 4 CKD (stage ≥4)

50 Quadruple oral therapy
- 13 SU+MET+DPP-4i+SGLT2i
- 37 SU+MET+DPP-4i+TZD

46 GLP-1RA (+SU+MET) therapy

Supplementary Fig. 1. Flow diagram of the study population. GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycosylated hemoglobin; CKD, chronic kidney disease; SU, sulfonylurea; MET, metformin; DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; TZD, thiazolidinedione.